Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-01-15

Clinical Trial Update: Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing TLK286 (Telcyta) to Gefitinib in locally advanced or metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Iressa (gefitinib)
  • Telcyta (TLK286)

Snippet

Sponsor: Telik | Conditions: Non Small Cell Lung Carcinoma | Phase 3 | Status: COMPLETED